Details for New Drug Application (NDA): 016042
✉ Email this page to a colleague
NDA 016042 describes DYAZIDE, which is a drug marketed by Glaxosmithkline Llc and is included in one NDA. Additional details are available on the DYAZIDE profile page.
The generic ingredient in DYAZIDE is hydrochlorothiazide; triamterene. There are thirty-two drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; triamterene profile page.
The generic ingredient in DYAZIDE is hydrochlorothiazide; triamterene. There are thirty-two drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; triamterene profile page.
Summary for 016042
| Tradename: | DYAZIDE |
| Applicant: | Glaxosmithkline Llc |
| Ingredient: | hydrochlorothiazide; triamterene |
| Patents: | 0 |
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 25MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 25MG;37.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Mar 3, 1994 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
